Indivi to Provide Digital Biomarkers for Herantis’ Phase 2 Parkinson’s Trial

New updates have been reported about Indivi.

Indivi is set to play a central role in Herantis Pharma’s planned Phase 2 proof-of-concept trial of HER-096 for Parkinson’s disease by supplying its smartphone-based digital biomarker platform, putting the Basel-based TechBio firm directly into a pivotal mid-stage neurology program. The platform will capture high-frequency, multi-domain measures of motor and cognitive performance, aiming to detect early treatment-related changes that conventional clinical endpoints often miss in proof-of-concept studies.

Herantis has optimized its double-blind, placebo-controlled, randomized Phase 2 study design to formally integrate Indivi’s tools alongside standard assessments, signaling confidence in Indivi’s technology and creating a high-visibility validation opportunity for its precision neuroscience offering. Indivi’s Chief Medical Officer emphasized that HER-096’s disease-modifying mechanism is well aligned with the company’s multimodal deep phenotyping approach, including its proprietary CoGames cognitive battery, positioning Indivi to demonstrate superior signal-to-noise in measuring drug effects and potentially strengthening its value proposition with current and future biopharma partners.